Delving into the Latest Updates on Technetium (99mTc) Macroaggregated Human Serum Albumin with Synapse

Overview

Basic Info

Drug Type

Chemical drugs, Diagnostic radiopharmaceuticals

Synonyms

Techne MAA

+ [1]

Target-

Action-

Mechanism-

Therapeutic Areas

Cardiovascular DiseasesRespiratory DiseasesNeoplasms

Active Indication

Pulmonary Vascular DiseaseLung Cancer

Inactive Indication-

Originator Organization

PDRadiopharma, Inc.

Active Organization

PDRadiopharma, Inc.

Mass General Brigham, Inc.

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

Japan (14 Jun 1977),

Pulmonary Vascular Disease

Regulation-

Login to view timeline

OBJECTIVETo evaluate whether a radioguided approach allows a higher intraoperative detection rate of adenoma and a minimally invasive parathyroidectomy (MIP), with the same or better cure rate of hyperparathyroidism secondary to parathyroid adenoma.METHODSThis was an observational, prospective, single-center study involving 254 consecutive patients with primary hyperparathyroidism, between 2017 and 2022. A total of 258 procedures were performed: 129 non radioguided (NRS) and 129 radioguided (RS) (112 with intravenous 99mTc- MIBI and 17 with ultrasound-guided intralesional 99mTc-MAA injection) with an intraoperative gamma probe and gamma camera. Follow-up was performed for at least one year.RESULTSThere were no differences between the groups in terms of age, sex, preoperative calcium or parathyroid hormone levels, adenoma localization with 99mTc-MIBI-gammagraphy and ultrasound, and surgical morbidity. Intraoperative surgical localization was 97.7% in both groups. Statistically significant differences supported RS: It allowed to perform MIP (RS: 96.9%, NRS 88.4%; p = 0.015), also in patients with previous neck surgery (RS: 75%, NRS: 28%; p = 0.019) and with ectopic adenomas (RS: 93.3%, NRS: 71.4%; p = 0.012). The operative time was significantly shorter (RS: 51 min, NRS: 59.79 min; p = 0.005). There were no significant differences in the postoperative complications between the groups. Biochemical cure at six months was achieved in RS: 97.7% and NRS: 93.8% (p = 0.12).CONCLUSIONSRadioguided MIP is useful in ectopic adenomas and in patients with previous cervical surgery and allows a minimally invasive approach more frequently. It is a safe surgery, easily reproducible by an endocrine surgeon and requires usual equipment found in operating rooms.

01 Mar 2024·Annals of Nuclear Medicine

Comparison of absorbed doses to the tumoral and non-tumoral liver in HCC patients undergoing 99mTc-MAA and 90Y-microspheres radioembolization

Article

Author: Khamwan, Kitiwat ; Sukprakun, Chanan ; Siricharoen, Punnarai ; Noipinit, Nut

PURPOSEThis study aimed to determine the absorbed doses in the tumoral-liver and non-tumoral liver of hepatocellular carcinoma (HCC) patients undergoing radioembolization with Yttrium-90 (⁹⁰Y) resin microspheres, and compared with those derived from ^99mTc-MAA using the partition model.METHODSA total of 42 HCC patients (28 males and 14 females, mean age 65 ± 11.51 years) who received 45 treatment sessions with ⁹⁰Y-microspheres between 2016 and 2021 were included. Pre-treatment ^99mTc-MAA and post-treatment ⁹⁰Y-bremsstrahlung SPECT/CT were acquired for each patient. Semi-automated segmentation of regions of interest (ROIs) was performed using MIM Encore software to determine the tumor-liver ratio (TLR) encompassing the liver volume, tumoral-liver, and lungs, and verified by both nuclear medicine physician and interventional radiologist. A partition dosimetry model was used to estimate the administered activity of ⁹⁰Y-microspheres and the absorbed doses to the tumoral-liver and non-tumoral liver. The student's paired t test and Bland-Altman plot were used for the statistical analysis.RESULTSThe mean TLR values obtained from ^99mTc-MAA SPECT/CT and ⁹⁰Y-bremsstrahlung SPECT/CT were 4.78 ± 3.51 and 2.73 ± 1.18, respectively. The mean planning administered activity of ⁹⁰Y-microspheres based on ^99mTc-MAA SPECT/CT was 1.56 ± 0.80 GBq, while the implanted administered activity was 2.53 ± 1.23 GBq (p value < 0.001). The mean absorbed doses in the tumoral-liver estimated from ^99mTc-MAA and ⁹⁰Y-bremsstrahlung SPECT/CT were 127.44 ± 4.36 Gy and 135.98 ± 6.30 Gy, respectively. The corresponding mean absorbed doses in the non-tumoral liver were 34.61 ± 13.93 Gy and 55.04 ± 16.36 Gy.CONCLUSIONThis study provides evidence that the administered activity of ⁹⁰Y-microspheres, as estimated from ⁹⁰Y-bremsstrahlung SPECT/CT, was significantly higher than that estimated from ^99mTc-MAA SPECT/CT resulted in increased absorbed doses in both the tumoral-liver and non-tumoral liver. However, ^99mTc-MAA SPECT/CT remains a valuable planning tool for predicting the distribution of ⁹⁰Y-microspheres in liver cancer treatment.

01 Jan 2023·Japanese Journal of Radiological Technology

<sup>99m</sup>Tc-macro aggregated albumin（MAA）投与時におけるシリンジと投与ルートの残留率評価—小児核医学検査を想定した低液量での検討—

Article

Author: Shibata, Shigeru ; Mimura, Hiroaki ; Kangai, Yoshiharu ; Inubushi, Masayuki ; Sato, Shun ; Nakamura, Yuto ; Abe, Toshinori

PURPOSEThe purpose of this study was to evaluate the residual radioactivity in the syringe and route of administration of a low fluid volume ^99mTc-macro aggregated albumin (MAA) intended for pediatric nuclear medicine examinations.METHODWe evaluated the residual characteristics, as the effect of elapsed time from drawing up of radiopharmaceuticals to plastic syringe to administration, and the effect of volume of ^99mTcO₄^- solution to be labeled, the effect of rinsed times of plastic syringe, effect of dose of calculated by consensus guidelines for pediatric nuclear medicine and residual location in injection sets with ^99mTc-MAA. Residual radioactivity was measured using planar images obtained by the gamma camera.RESULTSResidual radioactivity rate of ^99mTc-MAA, ^99mTc-MAG₃, ¹²³I-IMP showed 41.3±1.6%, 14.4±0.6%, 14.6±2.0%, respectively. ^99mTc-MAA clearly showed a higher residual rate. Residual radioactivity rate increased with the extension of the elapsed time, and reached a high value of 41.3% in 30 minutes. Residual radioactivity rate was dependent on the different volume of ^99mTcO₄^- to be labeled (4.0 ml and 8.0 ml). Residual radioactivity rate did not change when the number of rinsed was more than one. Residual rate was around 40% at all doses of calculated by consensus guidelines for pediatric nuclear medicine.CONCLUSION^99mTc-MAA showed the highest residual radioactivity rate among radiopharmaceuticals used in pediatric nuclear medicine examinations. The factor that most affected the residual radioactivity rate of ^99mTc-MAA was the elapsed time from draw up to the plastic syringe to administration.

100 Deals associated with Technetium (99mTc) Macroaggregated Human Serum Albumin

Login to view more data

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Pulmonary Vascular Disease	Japan	PDRadiopharma, Inc.	14 Jun 1977

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Lung Cancer	Phase 1	-	Mass General Brigham, Inc.	-

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


SNMMI2024	Not Applicable	-	-	99mTc-MAAsphere Radioembolization (99mTc-MAA planar and SPECT/CT)	rpepyuayun(xghrbcnssw) = vvfrdexovf zmbasgxoji (laetxcttnu )	-	09 Jun 2024
				90Y-Microsphere Radioembolization (90Y-microsphere SPECT/CT and PET/CT)	rpepyuayun(xghrbcnssw) = qjekhpxjrf zmbasgxoji (laetxcttnu )
SNMMI2024	Not Applicable	-	-	99mTc-MAA (90Y-Microspheres PET/CT)	ygnmghgido(ahzqlporrq) = D50 values displayed a strong correlation between planned and administered doses istetwipgf (ccecawhsck ) View more	-	09 Jun 2024
EANM2022	Not Applicable	-	-	99mTc-MAA (MAA1)	pcfqywvegy(lybaqxsefk) = vfpcorvvwz eytqhrncth (zocqgcesed )	-	22 Sep 2022
TARGET phantom study (EANM2022)	Not Applicable	-	-	99m Tc MAA (Standardized Protocol)	lbmqrsltfn(cynpkgjjpw) = xxvfsedhvc xqfhcxskea (unsqpmcgqs, 0.82)	-	22 Sep 2022
				99m Tc MAA (Site-Specific Protocol)	lbmqrsltfn(cynpkgjjpw) = edpvkdjclf xqfhcxskea (unsqpmcgqs )
TARGET Round Robin sub-study (EANM2022)	Not Applicable	Hepatocellular Carcinoma 90 Y glass microspheres	20	Yttrium-90 (Anatomic workflow)	ufunsrbbyl(rvuiduorrk) = tockjotjyc bcvbpthzfz (uttovfwcvo ) View more	-	22 Sep 2022
				Yttrium-9099m Tc-MAA (99m Tc-MAA SPECT workflow)	ufunsrbbyl(rvuiduorrk) = mlxwkjlydu bcvbpthzfz (uttovfwcvo ) View more
TARGET Study99m Tc-MAA (EANM2022)	Not Applicable	Hepatocellular Carcinoma	209	Y-90 Glass Microspheres (Anatomic Workflow)	(mvdfnvifwm): odds ratio = 1.22 (95% CI, 1.01 - 1.49), P-Value = 0.044 View more	-	22 Sep 2022
				Y-90 Glass Microspheres99m Tc-MAA Microspheres (99m Tc-MAA SPECT Workflow)
EANM2019	Not Applicable	Kidney Failure, Chronic	8	99m Tc-MAA (Patients with Peritoneal Leakage)	wyluviosgh(awzecoailp) = vcziwzfwjm rtbomdxwci (cpgcvgcyas )	-	18 Sep 2019
SNMMI2019	Not Applicable	Neoplasms	-	99mTc-MAA	pyeoqmqkqk(kuypfauglj) = edbekqivix sgzhqbdvom (yuayqssntd ) View more	-	21 May 2019
				99mTc-MAA (90Y-microspheres)	pyeoqmqkqk(kuypfauglj) = qikkpotjcx sgzhqbdvom (yuayqssntd ) View more
SNMMI2019	Not Applicable	-	50	99mTc-MAA (Planar scintigraphy)	pgktqbppgf(mewoveikcp) = ooalsgxixa cpkytqpmcr (fthpyvszgt, 1.1 - 32.6)	Positive	21 May 2019
				99mTc-MAA (SPECT/CT)	pgktqbppgf(mewoveikcp) = uxbiufekcz cpkytqpmcr (fthpyvszgt, 1.3 - 21.2)
EANM2018	Not Applicable	-	20	99m Tc-MAA (90 Y-TheraSphere)	gvhgbidocf(fjcoodpech) = hujjubdqsv wkkvccsrnr (tppmwzfkad ) View more	Positive	18 Sep 2018